BioAlliance Pharma presents phase III results with Loramyc® (miconazole Lauriad®) and ongoing phase II trial with clonidine Lauriad®

MASCC/ISOO 2010 International Symposium
(Vancouver, Canada, June 24-26, 2010)

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc® and clonidine Lauriad® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.
The 1st abstract: « Effect of Salivary Flow on Efficacy of Miconazole Buccal Tablet (MBT) for Treatment of oropharyngeal candidiasis (OPC) » presented the results of the post-hoc analysis of a European phase III trial with Loramyc® (miconazole Lauriad®), mucoadhesive buccal tablet.
Reduced salivary flow resulting from radiotherapy treatment for head and neck cancer markedly affects the efficacy of treatments of OPC. The objective of this post-hoc analysis was to evaluate the efficacy of miconazole Lauriad® 50mg once daily or miconazole oral gel 500mg four times daily in these patients with reduced salivary flow. It showed that miconazole Lauriad® was an effective topical treatment for OPC in patients with reduced salivary flow with the major convenience of once-daily dosing.
BioAlliance Pharma’s commercial partners for Loramyc® are Therabel in Europe and Strativa Pharmaceuticals (the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies Inc.) in the United States.
The ongoing phase II trial with clonidine Lauriad® was also presented: « A phase II, multicentre, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of Clonidine Lauriad® 50 μg and 100 μg mucoadhesive buccal tablet (MBT) applied once daily in the prevention and treatment of chemoradiotherapy-induced oral mucositis in patients with head and neck cancer ».
Clonidine Lauriad® uses the innovative muco-adhesive technology validated with Loramyc® and more recently with acyclovir Lauriad®. This new product is dedicated to the prevention and the treatment of radiotherapy and chemotherapy-induced oral mucositis in cancer patients.
« Multinational Association of Supportive Care in Cancer » (MASCC) is an international, multidisciplinary organization dedicated to supportive care for patients with cancer. In 1998 MASCC joined forces with the « International Society of Oral Oncology » (ISOO), an organization that addresses the management of complications arising in oral tissues secondary to cancer and its treatments.